JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• The Janus kinase 2 (JAK2) SH2-JH2 linker domain is crucial for negatively regulating JAK2 activity.
• Dysregulation of JAK2 signaling is a hallmark of myeloproliferative neoplasms (MPNs).

Purpose of the Study:

• To identify and characterize novel JAK2 mutations in patients with MPNs.
• To investigate the functional consequences of the identified JAK2 S523L mutation on JAK2 activity and cellular proliferation.

Main Methods:

• Genetic sequencing to identify mutations in JAK2.
• Functional assays using Ba/F3 cell lines expressing the erythropoietin receptor and JAK2 S523L.
• Analysis of patient clinical data and bone marrow morphology.

Main Results:

• A novel JAK2 mutation, S523L, was identified in the SH2-JH2 linker region of two MPN patients.
• In one patient, JAK2 S523L was associated with thrombocytosis and megakaryocytic hyperplasia without other mutations.
• The second patient presented with erythrocytosis and concurrent RUNX1 and BCORL1 mutations.
• JAK2 S523L expression induced interleukin-3-independent cell growth, indicating constitutive activation of the JAK2/STAT5 pathway.

Conclusions:

• The JAK2 S523L mutation represents a novel driver mutation in MPNs.
• Constitutive activation of JAK2/STAT5 signaling by JAK2 S523L contributes to MPN pathogenesis.
• This finding expands the mutational landscape of JAK2 in MPNs and highlights the importance of the linker domain.